Insider · CIK 0001806384
Marlio Charles Mosseri
Files at NVCT (Nuvectis Pharma, Inc.). First filing Dec 16, 2024, latest Jul 1, 2026.
In brief
Marlio Charles Mosseri files SEC Form 4 as 10% owner at NVCT (Nuvectis Pharma, Inc.). Since Dec 16, 2024, Marlio Charles Mosseri has reported 9 open-market buys worth $3.2M and 0 open-market sells worth $0, the latest filed on Jul 1, 2026.
After Marlio Charles Mosseri's past buys, the stock trailed the S&P 500 by a median 18.6% over six months (n = 8), and 38% of those buys were ahead of the index at six months. InsiderTell labels that a negative record.
The newest scored trade: bought $916k of NVCT on Jun 30, 2026, filed Jul 1, 2026, scored 47 (moderate). In the last 12 months: 2 buys worth $1.9M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NVCT: Nuvectis Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 47Moderate | Nuvectis Pharma, Inc. | $916k 50,000 shares | +2% | +225% from low-36% from high | |
| 57Moderate | Nuvectis Pharma, Inc. | $957k 154,770 shares | +5% | +33% from low-45% from high | |
| 17Weak | NVCTbuy Nuvectis Pharma, Inc. | $45k 5,603 shares | +0% | +80% from low-26% from high | |
| 29Weak | NVCTbuy Nuvectis Pharma, Inc. | $270k 33,442 shares | +1% | +79% from low-26% from high | |
| 22Weak | NVCTbuy Nuvectis Pharma, Inc. | $172k 21,167 shares | +1% | +86% from low-24% from high | |
| 24Weak | NVCTbuy Nuvectis Pharma, Inc. | $247k 27,662 shares | +1% | +104% from low-16% from high | |
| 19Weak | NVCTbuy Nuvectis Pharma, Inc. | $236k 27,411 shares | +1% | +98% from low-18% from high | |
| 24Weak | Nuvectis Pharma, Inc. | $80k 17,000 shares | +1% | - | |
| 28Weak | Nuvectis Pharma, Inc. | $229k 49,121 shares | +2% | - |
Transactions
Every row this insider has filed, 25 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +50,000 | $18.32 | $916k | 3,186,576 | Jul 1, 2026 |
| Oct 23, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +46,900 | $6.06 | $284k | 3,028,706 | Oct 29, 2025 |
| Oct 24, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +35,034 | $6.15 | $215k | 3,063,740 | Oct 29, 2025 |
| Oct 27, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +72,836 | $6.28 | $457k | 3,136,576 | Oct 29, 2025 |
| Jun 20, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +5,603 | $7.99 | $45k | 2,981,806 | Jun 24, 2025 |
| Jun 17, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +5,399 | $8.11 | $44k | 2,948,160 | Jun 20, 2025 |
| Jun 18, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +28,043 | $8.05 | $226k | 2,976,203 | Jun 20, 2025 |
| May 12, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +21,167 | $8.11 | $172k | 2,942,761 | May 13, 2025 |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +100 | $8.99 | $899 | 2,909,032 | May 12, 2025 |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +100 | $8.71 | $871 | 2,909,132 | May 12, 2025 |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +2,400 | $8.97 | $22k | 2,911,532 | May 12, 2025 |
| May 9, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +9,850 | $8.95 | $88k | 2,921,382 | May 12, 2025 |
| May 9, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +9,817 | $8.90 | $87k | 2,931,199 | May 12, 2025 |
| May 9, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +5,395 | $8.98 | $48k | 2,936,594 | May 12, 2025 |
| May 6, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +2,340 | $8.40 | $20k | 2,886,461 | May 9, 2025 |
| May 6, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +10,104 | $8.64 | $87k | 2,896,565 | May 9, 2025 |
| May 7, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +2,703 | $8.40 | $23k | 2,899,268 | May 9, 2025 |
| May 7, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +9,614 | $8.64 | $83k | 2,908,882 | May 9, 2025 |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +50 | $8.65 | $433 | 2,908,932 | May 9, 2025 |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +100 | $8.65 | $865 | 2,909,032 | May 9, 2025 |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +100 | $8.65 | $865 | 2,909,132 | May 9, 2025 |
| May 8, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stockindirect: By Emerald Hill Ventures SARL SPF. | +2,400 | $8.65 | $21k | 2,911,532 | May 9, 2025 |
| Dec 13, 2024 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stock | +17,000 | $4.70 | $80k | 2,612,000 | Dec 16, 2024 |
| Dec 12, 2024 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stock | +32,121 | $4.64 | $149k | 2,627,121 | Dec 16, 2024 |
| Dec 13, 2024 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stock | +17,000 | $4.70 | $80k | 2,644,121 | Dec 16, 2024 |
Questions about Marlio Charles Mosseri
Answered from the filings on this page, as of the latest one.
Is Marlio Charles Mosseri buying or selling?
In the last 12 months Marlio Charles Mosseri reported 2 open-market buys worth $1.9M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $916k of NVCT on Jun 30, 2026. Grants, option exercises and tax withholding are not counted.
How did Marlio Charles Mosseri's past buys perform?
Measured from the first close after each filing, the stock trailed the S&P 500 by a median 18.6% over six months across 8 past buys, with 38% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does Marlio Charles Mosseri file Form 4?
Marlio Charles Mosseri has filed Form 4 at NVCT (Nuvectis Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.